Paxil Settlements Reached in Hundreds of Birth Defect Lawsuits

GlaxoSmithKline has agreed to settle Paxil birth defect lawsuits brought on behalf of nearly 200 people. The settlements come after the company was hit with a $2.5 million verdict in the first case to go to trial last year. 

There are an estimated 600 Paxil lawsuits over birth defects filed against the drugmaker as part of a mass tort in Philadelphia, all involving allegations that the company failed to warn consumers and doctors that use of Paxil during pregnancy could lead to congenital heart defects in newborns.

According to an order signed by Judge Sandra Mazer Moss, who is overseeing the Paxil litigation, GlaxoSmithKline has agreed to settle 190 of those cases. In addition, according to a report by The Legal Intelligencer, Paxil attorneys have settled about another 100 cases, some of which were not yet filed.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

In October, a Philadelphia jury ruled against Glaxo, awarding $2.5 million in compensatory damages to the family of a child born with three heart defects. While Glaxo initially indicated they would appeal the verdict, the case was among those settled last week. However, no details on any of the Paxil settlement terms have been disclosed.

Paxil (paroxetine) is a selective serotonin reuptake inhibitor prescribed to treat depression. Approved in 1992, it has become one of the most commonly prescribed drugs in the United States, with sales of just under $1 billion in 2008.

The use of Paxil during pregnancy has been linked to an increased risk of persistent pulmonary hypertension in newborns (PPHN) and other heart problems. In lawsuits pending throughout the United States, plaintiffs allege that GlaxoSmithKline hid test data and misled doctors and consumers about the risk.

In December 2005, the FDA issued an alert about the risk of birth defects from Paxil after studies showed the drug could increase the risk of the heart defects when taken during the first three months of pregnancy. At that time, the agency also required GlaxoSmithKline to update the warning label to include information about the risk of birth defects from Paxil side effects.

Not counting the 190 cases just settled, GlaxoSmithKline has reportedly paid about $1 billion to settle Paxil lawsuits, including claims that the drug also causes suicides, addiction and other problems, in addition to birth defects.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted today)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted yesterday)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).